BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: In two other studies, a cell death response was triggered on primary CML CD34+ quiescent cells by a triple combination associating ABT-737 to block BCL2 and Bcl-xL, Nilotinib to inhibit BCR-ABL and a MDM2 inhibitor such as Nutlin3a [24] or DS-5272 [25] to restore p53 activation.